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The establishment of a large collaborative trial
programme in the adjuvant treatment of colon cancer
J Wils
The Laurentius Hospital, Roermond, The Netherlands
Summary After many years, during which the assumption prevailed that adjuvant chemotherapy was of no benefit in patients with resectable
adenocarcinoma of the colon, findings of several large USA studies published from the late 1980s have caused a marked shift in surgical and
medical opinion. Although results in patients with Dukes' B disease have not shown any clear benefit, the efficacy of adjuvant chemotherapy
has nevertheless been shown in those with Dukes' C colon cancer. As a result, the Mayo regimen of 5-fluorouracil (5-FU) with low-dose
leucovorin (LV) has become accepted as standard adjuvant therapy in these patients. However, the disadvantages associated with standard
5-FU-based treatment, particularly those relating to its toxicity and inconvenience of administration, have generated interest in other regimens
and agents. The novel direct and specific thymidylate synthase inhibitor raltitrexed ('Tomudex') has been associated with similar objective
response rates to standard therapy with 5-FU plus LV in patients with advanced colorectal cancer. In addition, raltitrexed has an attractive
tolerability profile compared with that of 5-FU plus LV (specifically with respect to lower incidences of mucositis and leucopenia), and the
simple 3-weekly administration schedule may be considered more convenient by many patients and may reduce healthcare resource
consumption. To investigate alternatives to the Mayo regimen in the adjuvant treatment of Dukes' C adenocarcinoma of the colon, two large
European trials have been set up: (1) PETACC-1 (first Pan-European Trial for Adjuvant Treatment of Colon Cancer), to compare raltitrexed
with the Mayo regimen of 5-FU and low-dose LV; (2) PETACC-2 (second Pan-European Trial), to compare the Mayo regimen with three
regimens in which 5-FU is given by prolonged infusion. These trials will provide valuable international data to add to those from the USA and
will assess the place of raltitrexed in the adjuvant treatment of Dukes' C colon cancer. They will also compare directly for the first time
infusional and bolus 5-FU regimens in the adjuvant setting.
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Colorectal cancer is a major cause of mortality and morbidity in
industrialized countries. Each year, more than 300 000 new cases
are diagnosed and over 150 000 patients die of the disease in
Europe and the USA (Esteve etal, 1993; Boring et al, 1994). Ofall
patients who present with colorectal cancer, approximately three-
quarters are potentially curable with radical resection of the
primary tumour (Coperchini and Zalcberg, 1994-5). In spite of
this, however, the prognosis associated with this malignancy
remains poor, with at least 50% of patients dying of subsequent
metastatic disease within 5 years (Coperchini and Zalcberg,
1994-5; Bleiberg, 1997). It is for this reason that adjuvant therapy
(chemo-, radio- or immunotherapy) is added to surgery.
ADJUVANT CHEMOTHERAPY IN COLON
CANCER
Adjuvant treatment may be defined as treatment given in an attempt
to eradicate clinically undetectable metastases, and to thus prevent
local lymphatic spread and recurrence after potentially curative
surgical resection of the primary tumour. The first adjuvant
chemotherapy trials in colorectal cancer were carried out in the
1960s (van Triest et al, 1995). However, no significant survival
benefit was shown forpatients receiving adjuvant chemotherapy for
many years (one ofthe reasons for early negative results may have
been the low intensity of the treatments used in these studies); in
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addition, the majority of oncologists considered such treatment to
be of no advantage for patients until the late 1980s when two large
co-operative group trials showed significant benefits with adjuvant
chemotherapy in patients with resected colon cancer (Wolmark et
al, 1988; Laurie et al, 1989). In a trial with 401 patients with surgi-
cally treated Dukes' B2 or C disease, the North Central Cancer
TreatmentGroup (NCCTG) showed asignificant(P =0.003) reduc-
tion in recurrence rate when the anthelmintic drug levamisole was
given as adjuvant therapy in combination with 5-fluorouracil
(5-FU). Patients wererandomized to aconttol group (surgery alone)
or to treatment with levamisole (150 mg/day for 3 days every 2
weeks for 1 year) or levamisole plus 5-FU (450 mg m-2 bolus daily
for 5 days followed by 450 mg m-2 weekly, starting on day 28 and
continued for 1 year). No statistically significant overall survival
advantage was conferred by adjuvant treatment, but a retrospective
subset analysis showed a significant survival advantage for
levamisole plus 5-FU in patients with Dukes' C disease. Although
the use of adjuvant chemotherapy remained controversial during
this period, a breakthrough was finally made in 1990 when Moertel
and colleagues (1990) published theirpivotal findings in 318 evalu-
able patients with Dukes' B and 929 with Dukes' C disease.
In the Moertel study, 315 of the 929 patients with Dukes' C
disease were randomized to a control group (surgery only with
no further planned treatment), 310 to levamisole and 304 to
levamisole plus 5-FU (same regimens as in the NCCTG study)
(Laurie et al, 1989). After a median 3-yearfollow-up, therapy with
levamisole plus 5-FU reduced the risk of recurrence of cancer by
'Tomudex' is a trademark, the property ofZeneca.
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Figure 1 (A) Three-year event-free survival and (B) overall survival after
treatment with surgery only (control) or surgery and adjuvant chemotherapy
with 5-fluorouracil plus leucovorin in patients with Dukes' B or C colon cancer
in three randomized clinical trials. Median follow-up times were 37 and 40
months for adjuvant and control groups respectively (IMPACT, 1990)
an estimated 41% relative to control (P < 0.0001), whereas
therapy with levamisole alone produced no significant effect.
Rates of recurrence were reduced for all sites, but particularly for
sites outside the abdominal cavity. The overall death rate was
reduced with levamisole plus 5-FU by 33% (P = 0.006). No clear
trends were apparent in patients with Dukes' B2 disease. These
results were confirmed in a later report after a median follow-up
period of 6.5 years (Moertel et al, 1995). These findings led the
USA National Cancer Institute to convene a consensus conference
at which the adoption of 5-FU plus levamisole as standard adju-
vant therapy for Dukes' C colon cancer was recommended;
ongoing trials that did not offer this treatment option were termi-
nated (National Institutes of Health Consensus Development
Conference Statement, 1990).
Further data to corroborate the above findings were presented in
1995 by the IMPACT (International Multicentre Pooled Analysis
of Colon Cancer Trials) investigators (IMPACT, 1995). Results
were pooled from three randomized multicentre co-operative group
trials in 1526 patients with resected Dukes' B (56%) or C (44%)
adenocarcinoma of the colon. Each trial used the same adjuvant
treatment regimen of 5-FU 370-400 mg m-2 plus leucovorin (LV)
200 mg m-2 daily [Machover regimen (Machover et al, 1986)] for 5
days every 28 days for six cycles. Of the 1493 evaluable patients,
736 were in the adjuvant treatment group and 757 were in the
control (surgery only) group. After median follow-up times of 40
and 37 months for the adjuvant chemotherapy and control groups,
respectively, 5-FU plus LV was associated with significant reduc-
tions in mortality (22%, P = 0.029) and adverse events (35%,
P < 0.0001), and increases in 3-year event-free survival (from 62%
to 71%, hazard ratio 0.67, P < 0.0001) and overall survival (from
78% to 83%, hazard ratio 0.77, P = 0.018). Figure 1 illustrates
survival for the different stages of disease and shows the much
greater effect ofadjuvant therapy in Dukes' C patients.
Improved survival with adjuvant chemotherapy was also shown
by O'Connell and colleagues (1997) in a recent report of mature
results from the NCCTG and the Mayo Clinic in the USA. In this
study, 317 patients with high-risk TNM (tumour, node, metastases
classification) stage II or III adenocarcinoma of the colon were
randomized 3-4 weeks after surgery to adjuvant chemotherapy
with six cycles of5-FU 425 mg m-2 plus low-dose LV (20 mg m-2)
(Mayo regimen) by rapid intravenous injection every day for 5
days every 4-5 weeks for six cycles or observation only. Of the
evaluable patients, 62 of 151 control patients (41%) and 43 of 158
(27%) who had received chemotherapy had relapsed after a
median 72 months (P = 0.001). In the control and adjuvant
chemotherapy groups, mortality rates were 40% and 28% respec-
tively (P = 0.01). The relative improvements seen in the patients
treated with chemotherapy were sufficient after only 1 year for the
investigators to discontinue the study prematurely on the grounds
that it was no longer ethically justifiable to randomize patients to
surgery alone.
Clinical studies have also been carried out to ascertain the
relative efficacy of 5-FU modulated with levamisole, LV or both,
Table 1 Adjuvant chemotherapy treatment regimens in NSABP trial C-04 in 2151 patients with Dukes' B or C colon cancer (Wolmark et al, 1996)
Treatment arm Regimen Time on treatment
5-FU + leucovorin (LV) 5-FU 500 mg m-2 Six cycles
LV 500 mg m-2 weekly for 6 weeks
5-FU + levamisole (LEV) 5-FU 450 mg m-2 daily for 5 days, then weekly after day 29 1 year
for 1 year
LEV 50 mg three times daily orally for 3 days every 2 weeks
5-FU + LV + LEV 5-FU 500 mg m-2 + LV 500 mg m-2 weekly for 6 weeks 5-FU + LV, six cycles
LEV 50 mg three times daily orally for 3 days every 2 weeks LEV, 1 year
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Figure 2 Five-year disease-free survival (DFS) and overall survival in the
NSABP C-04 study (Wolmark et al, 1996). Of 2151 patients who were
randomized to treatment, 49% have contributed survival information over the
mean 63.4-month follow-up period
given for periods of 6 or 12 months. The National Surgical
Adjuvant Breast and Bowel Project (NSABP) group has recently
reported on its protocol C-04, in which 2151 patients with
resectable Dukes' B or C colon cancer were randomized to adju-
vant chemotherapy with the three treatment options shown in
Table 1 (Wolmark et al, 1996). Although there were no significant
differences between the three arms in disease-free and overall
survival, pairwise comparisons indicated an advantage for 5-FU
modulated with LV (Figure 2).
Preliminary results are also available from a large USA study
(INT-0089), started in 1988, in which patients with high-risk stage
II or III (TNM) colon cancer were originally randomized to adju-
vant therapy with 5-FU with high- or low-dose LV or to a control
arm (surgery only) (Haller et al, 1996). Recruitment to the control
arm was stopped in 1989 after reports ofefficacy ofadjuvant 5-FU
plus levamisole (described earlier), and a 5-FU plus levamisole
treatment arm was added to the trial protocol. A fourth arm was
also added, in which patients received a combination of the
standard levamisole regimen and 5-FU plus low-dose LV. The
regimens are described in more detail in Table 2. A total of 3759
patients entered the trial, 80% ofwhom had stage III disease. After
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Figure 3 Survival rates after median follow-up of 4.2 years in 890 evaluable
patients with high-risk TNM stage 11 or IlIl resected colon cancer. The four
adjuvant chemotherapy regimens were: (1) 5-fluorouracil 450 mg m-2 daily
for 5 days, then 450 mg m-2 weekly from day 29; levamisole 50 mg orally
three times daily for 3 days every 2 weeks for 6 months (5-FU/LEV
6 months); (2) as above for 12 months (5-FU/LEV 12 months); (3) 5-FU
370 mg m-2 plus leucovorin 20 mg m-2 daily for 5 days every 4-5 weeks;
levamisole 50 mg orally three times daily for 3 days every 2 weeks for
6 months (5-FU/LV/LEV 6 months); (4) as above for 12 months (5-FU/LV/LEV
12 months)
treatment comparisons were mature, with no significant differ-
ences between treatments and no apparent additional benefit of
levamisole added to 5-FU plus low-dose LV. A subsequent report
from this trial stated that 6 months of adjuvant therapy with 5-FU
plus LV was at least as effective as the standard 12-month regimen
of5-FU plus levamisole (Haller et al, 1997).
Results from ajoint trial ofthe NCCTG and the National Cancer
Institute ofCanada (NCIC), in which 6- and 12-month regimens of
5-FU and LV were compared with 5-FU, LV and levamisole,
showed that 12 months' chemotherapy offers no advantage over 6
months' treatment and that 5-FU plus levamisole for 6 months is
inferior to 5-FU plus levamisole and LV for 6 months (Figure 3)
(O'Connell et al, 1996).
ADJUVANT CHEMOTHERAPY: THE CURRENT
POSITION
These results strongly support the use of post-operative adjuvant
chemotherapy, particularly in patients with Dukes' C colon cancer,
although its use in Dukes' B disease remains controversial.
Available data indicate 5-FU with LV, given for 6 months, to be at
least as effective as 5-FU plus levamisole for 12 months. Thus, the
Table 2 Adjuvant chemotherapy treatment regimens in INT-0089 in 3759 patients with TNM stage 11 or IlIl colon cancer (Haller et al, 1996)
Treatment arm Regimen Time on treatment (months)
5-FU + low-dose (LD) 5-FU 425 mg m-2 daily for 5 days 6
leucovorin (LV) LV 20 mg m-2 daily for 5 days; weeks 1, 5, 9, 14, 19 and 24
5-FU + high-dose (HD) LV 5-FU 500 mg m-2 weekly for 6 weeks 8
LV 500 mg m-2 weekly for 6 weeks; every 2 months for four
cycles
5-FU + levamisole (LEV) 5-FU 450 mg m-2 daily for 5 days, then every week for 12 12
months beginning at week 5
LEV 50 mg three times daily orally for 3 days every 2 weeks
5-FU + LDLV + LEV 5-FU 425 mg m-2 daily for 5 days 12
LV 20 mg m-2 daily for 5 days
LEV 50 mg three times daily orally for 3 days every 2 weeks
British Journal ofCancer(1998) 77(Supplement2), 23-28 0 CancerResearch Campaign 199826 J Wils
Table 3 Groups participating in the Pan-European adjuvant chemotherapy studies
Country Group Initials/acronym Chief investigators
Canada Canadian Group for Colorectal Cancer CGCRC M Vincent
Egypt Egyptian Cancer Society ECS M El-Sarafy, H Khaled,
S Omar
Europe European Organization for Research and EORTC - GITCCG J Wils, D Nitti, B Paillot,
Treatment of Cancer - Gastrointestinal R Sylvester
Tract Cancer Co-operative Group
France Fondation Fran9aise de Cancerologie FFCD L Bedenne, JF Seitz
Digestive
Germany Arbeitsgemeinschaft lnternistische AIO/CAO K Hoffken, H Wilke,
Onkologie/Chirurgische C-H Kohne, H-J Meyer,
Arbeitsgemeinschaft Onkologie K Lorenz
Italy Gruppo Interdisciplinare Valutazione GIVIO; GISCAD R Labianca, V Torri
Interventi in Oncologia; Gruppo Italiano
Studio Carcinomi Apparato Digerenti
Intergruppo Nazionale Terapia Adjuvante INTACC (GOIRC, A Sobrero, F Di
Carcinoma Colon GOPTAD, IOR, Costanzo, P Bruzzi,
IST Genova) L Dogliotti, A Falcone,
L Frassinetti, R Rosso
Gruppo Oncologico-Chirurgico GOCCI F Tonelli, T Mazzei,
Cooperativo Italiano E Mini
Portugal Grupo Cooperativo Cancro Digestivo; GCCD; APIO J Guimaraes Dos
Associao Portuguesa Investigaca Santos, E Sanches
Oncologio
Spain Grupo Espanol Tratamiento Tumores TTD A Carrato, E Diaz-Rubio,
Digestivos E Aranda
UK Clinical Trials Unit QUASAR D Kerr, C McArdle,
R Gray
Mayo regimen of 5-FU 425 mg m-2 (370 mg m-2 in some centres)
plus LV 20 mg m-2 for 5 days every 4-5 weeks (Poon et al, 1989)
is currently considered to be the preferred adjuvant treatment in
patients with resected Dukes' C colon cancer. However, regimens
based on 5-FU are complicated to administer and are associated
with troublesome toxicity, particularly mucositis and leucopenia
(Petrelli et al, 1987, 1989), which necessitates dose reduction
and/or delay in treatment (Advanced Colorectal Cancer Meta-
analysis Project, 1992). Indeed, in one of the above studies
(Wolmark et al, 1996), toxicity ofWHO grade 3 severity or greater
was reported in 36% ofpatients who received 5-FU plus LV, 38%
ofthose who received 5-FU, LV and levamisole and 28% of those
who received 5-FU plus levamisole. Thus, there is interest in the
use ofagents in adjuvant therapy that are as effective as modulated
5-FU but that have more favourable tolerability profiles and less
complex administration schedules.
Raltitrexed, a direct and specific inhibitor of thymidylate
synthase (TS), is an interesting new candidate for the adjuvant
therapy of surgically managed cancer ofthe colon. Raltitrexed has
already been shown in phase II and III studies to be ofsimilar effi-
cacy to 5-FU modulated with LV in the management of advanced
colorectal cancer (Kerr, 1997; Blackledge, 1998). Palliative bene-
fits were reported with both drugs, and raltitrexed was associated
with tolerability advantages compared with 5-FU, especially in
early treatment cycles, which reflected significant quality-of-life
benefits for raltitrexed in cycle 1.
Diarrhoea, mucositis, leucopenia and alopecia were markedly
less frequent and less severe with raltitrexed than with 5-FU + LV
in all phase III studies. Raltitrexed was associated with elevated
hepatic transaminase levels, but these were of no clinical conse-
quence and declined with continued treatment. The reduced
frequency of clinically significant adverse effects with raltitrexed
5-FU 3.5 g m2 48-h infusion
/ once a week for 24 weeks
5-FU 2.6 g m-2 24-h infusion +
leucovorin 500 mg m-2 2-h
/ infusion once weekly for 6 weeks,
Group 2 *repeated on day 57 for three cycles
\ (24 weeks)
5-FU 400 mg m2 bolus +
600 mg m-2 22-h infusion with
leucovorin 200 mg m2 2-h
infusion on 2 days every 2 weeks
for 24 weeks
Figure 4 Regimens for high-dose infusional 5-fluorouracil in PETACC-2
was reflected by significantly fewer toxicity-related dosage reduc-
tions in early treatment cycles in patients treated with raltitrexed
(Zalcberg, 1997). The convenient administration schedule for this
drug (one 15-min infusion every 3 weeks) is also of interest, as it
reduces the frequency of hospital attendance by patients with
consequent beneficial effects on quality of life and on healthcare
resource consumption. These benefits of therapy with raltitrexed
may prove particularly advantageous in the adjuvant setting, in
which patients may be asymptomatic before chemotherapy.
NEW EUROPEAN CLINICAL STUDIES OF
ADJUVANT RALTITREXED AND 5-FU IN DUKES'
C COLON CANCER
Large studies ofthe efficacy ofadjuvant chemotherapy in resected
colon cancer have, to date, been carried out by investigators in
the USA. Non-USA data in this area of study are scarce. Two
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international studies have been proposed to determine the efficacy
of raltitrexed and various infusional 5-FU regimens relative to
currently accepted adjuvant treatment. In order to recruit the large
numbers ofpatients needed, these studies will involve the collabo-
ration of international co-operative groups with expertise in the
study and treatment ofcolorectal cancer (Table 3).
The first Pan-European Trial for Adjuvant Treatment of Colon
Cancer (PETACC-1), which will compare raltitrexed with the
Mayo (low-dose LV) regimen as post-surgical adjuvant treatment
in patients with Dukes' C colon cancer who have undergone cura-
tive radical resection within the 42 days preceding enrolment, was
initiated in February 1998. Primary objectives are to determine
recurrence-free and overall survival rates; the secondary objective
will be to compare the toxicities of the two regimens. PETACC-1
is a randomized, multicentre, international, intergroup phase III
trial that will be conducted in approximately 400 centres. The
recruitment target is around 3000 patients with histologically
confirmed Dukes' C adenocarcinoma of the colon. Each patient
will be required to have received no prior chemotherapy and to
have a WHO performance status of0 to 1, and will be randomized
to raltitrexed 3 mg m-2 as a 15-min intravenous infusion once
every 3 weeks for eight cycles or bolus 5-FU 425 or 370 mg m-2
with LV 20 mg m-2 for 5 days every 4 weeks for six cycles.
Treatment will last for 24 weeks.
Patients will be assessed at least once every 6 months for the
first 3 years after randomization ofthe last patient and at least once
a year thereafter until death. To maintain the statistical power of
the study, recurrence-free and overall survival will not be finally
analysed until a total of703 events/deaths have been reported. It is
anticipated that analyses will be carried out at 1.5 (for recurrence-
free survival) and 3 (for survival) years and that results will be
available in the year 2002.
A second study, PETACC-2, will be carried out at the same time
to compare the Mayo regimen (5-FU 370 or 425 mg m-2 plus LV
20 mg m-2 for 5 days every 4 weeks for six cycles) with three high-
dose infusional 5-FU regimens. Interest in such a comparison
stems from observations indicating that 5-FU acts in different
ways depending on whether it is administered over a short period
as an intravenous bolus injection or rapid infusion (e.g. up to
15 min) or as a prolonged infusion (Sobrero et al, 1997). Three
infusion regimens are being assessed in the infusion arm of the
trial (Figure 4); this itself is noteworthy, because these regimens
have never been directly compared, but the assumption is that no
major differences between the three regimens exist.
CONCLUSIONS
This is an exciting and interesting time for all those involved in the
treatment of resected adenocarcinoma of the'colon. Now that the
benefit ofadjuvant chemotherapy to patients with Dukes' C disease
has been clarified in USA centres, it is time to move to the next
stage of research to assess the benefit of alternatives to the Mayo
regimen of 5-FU with low-dose LV. These alternatives include
raltitrexed and various infusional 5-FU regimens. To match the
power of the USA studies, it is necessary to organize collaborative
efforts with the global involvement of experienced teams. It is
anticipated that PETACC-1 and PETACC-2 will further enhance
our understanding ofand ability to treat resectable adenocarcinoma
of the colon, and will provide valuable insight into new treatment
regimens that may have advantages over existing therapies.
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